The white paper ‘Antibiotic therapy: everyone’s business’ is the result of fruitful discussions between professionals in the sector during a conference-debate and a temporary think tank in June and September 2024.
Produced at the request of Pfizer in partnership with the Pasteur Institute, Biomérieux, BEAM Alliance, the National Industry Council, and with the support of the Scientific Council’s Antibiotic Resistance Working Group, this book addresses three fundamental areas:
- Promote prevention practices, infection control and the proper use of antibiotics.
- Promoting R&D with the aim of fostering innovation and preserving the effectiveness of existing antibiotics
- Rethinking antibiotic treatment funding models
White book : “Antibiotic therapy: everyone’s business”
‘In 2015, the report ’Tous ensemble, sauvons les antibiotiques‘ (Let’s work together to save antibiotics) highlighted the urgent need to make antibiotic therapy a public health priority in response to the overuse of antibiotics and antibiotic resistance. Ten years later, these challenges remain pressing.’